Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CASTLE BIOSCIENCES INC
CSTL | US
21.01
USD-0.59
-2.73%
CSTL | US
Loading StockChartView...
About CASTLE BIOSCIENCES INC
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
05/06/2026
Close
21.01
Open
21.57
High
21.78
Low
20.99
Castle Biosciences Inc. a commercial-stage diagnostics company focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood Texas.
View LessCSTL | US
Risk
96.3
Sharpe
0.29
Luna's Score
52/100
Recommendation
Hold
Luna says (CSTL | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
74.8%1 month
96.3%3 months
64.0%6 months
56.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.21
Debt to equity
0.06
Debt to assets
0.05
Ent. to EBITDA
75.04
Ent. to rev.
2.44
PEG
-
Other Fundamentals
EBITDA
-2.67M
MarketCap
582.75M
MarketCap(USD)
582.75M
Div. yield
-
Op. margin
5.76
Erngs. growth
-92.60
Rev. growth
73.50
Ret. on equity
-0.77
Short ratio
4.87
Short perc.
6.00
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.65
Range1M
7.51
Range3M
10.08
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.40
Price X volume
4.36M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 75.04 | 12.67 | Expensive |
| Ent. to Revenue | 2.44 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 2.21 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 64.03 | 59.59 | Par |
| Debt to Equity | 0.06 | -14.36 | Expensive |
| Debt to Assets | 0.05 | 0.34 | Cheaper |
| Market Cap | 582.75M | 13.71B | Emerging |
